Jazz Pharmaceuticals JAZZ
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 88th percentile, 5-year average 60.8x
#2745 of 2996 stocks by PE (1 = cheapest)
Near the top of its 5-year range · 96th percentile, 5-year average 2.4x
#4106 of 5338 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 88th percentile, 5-year average 2.4x
#3382 of 5161 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 3.53 | – | 2.43 | 96% (pricier than usual) | #4106 of 5338 (1 = cheapest) |
| PE | 68.12 | 11.72 | 60.77 | 88% (pricier than usual) | #2745 of 2996 (1 = cheapest) |
| PS | 3.13 | 2.96 | 2.39 | 88% (pricier than usual) | #3382 of 5161 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on JAZZ.
Sign in to join the discussion.